SCHEMBL7071263

SCHEMBL7071263

CCCC(C(N)=O)C(CC(C)C)C(=O)N1CCN(c2cccc(C(F)(F)F)c2)CC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.51
LMNA P02545 5/20 0.50
ALDH1A1 P00352 2/20 0.50
L3MBTL1 Q9Y468 2/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
NPSR1 Q6W5P4 2/20 0.49
MEN1 O00255 1/20 0.49
CYP1A2 P05177 1/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2D6 P10635 1/20 0.49
CYP2C9 P11712 1/20 0.49
CYP2C19 P33261 1/20 0.49
KMT2A Q03164 1/20 0.49
HSD17B10 Q99714 1/20 0.48
TRPV1 Q8NER1 1/20 0.48
TSHR P16473 3/20 0.48
HTT P42858 2/20 0.48
GAA P10253 1/20 0.48
MAPK1 P28482 1/20 0.47
RAB9A P51151 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7067044 1.00 POLB (0.51) POLBLMNAALDH1A1L3MBTL1SMN1; SMN2
SCHEMBL7065713 0.89 CA12 (0.48) MEN1CYP3A4KMT2AHTT
SCHEMBL7065717 0.89 CA12 (0.48) MEN1CYP3A4KMT2AHTT
SCHEMBL7069253 0.86 LMNA (0.55) LMNAALDH1A1SMN1; SMN2NPSR1MEN1
SCHEMBL7069249 0.86 LMNA (0.55) LMNAALDH1A1SMN1; SMN2NPSR1MEN1
SCHEMBL7067097 0.86 P2RY12 (0.45) LMNAALDH1A1NPSR1TSHRHTT
SCHEMBL7067098 0.86 P2RY12 (0.45) LMNAALDH1A1NPSR1TSHRHTT
SCHEMBL7087657 0.84 GAA (0.51) POLBLMNAALDH1A1SMN1; SMN2NPSR1
SCHEMBL7087655 0.84 GAA (0.51) POLBLMNAALDH1A1SMN1; SMN2NPSR1
SCHEMBL7066757 0.84 DRD2 (0.47) LMNAALDH1A1MEN1CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030232985-A1 Succinoylamino heterocycles as inhibitors of a beta protein production THOMPSON LORIN A (US) 2003-12-18 US disclosed
US-20030073701-A1 Succinoylamino heterocycles as inhibitors of a beta protein production BRISTOL-MYERS SQUIBB PHARMA COMPANY 2003-04-17 US disclosed
EP-1268454-A1 SUCCINOYLAMINO HETEROCYCLES AS INHIBITORS OF A-BETA PROTEIN PRODUCTION Bristol-Myers Squibb Pharma Company (US) 2003-01-02 EP disclosed
WO-2001074796-A1 SUCCINOYLAMINO HETEROCYCLES AS INHIBITORS OF Aβ PROTEIN PRODUCTION BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2001-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073701-A1 Succinoylamino heterocycles as inhibitors of a beta protein production APP, BACE1, APH1A POLB 2847/4885LMNA 911/4885ALDH1A1 3091/4885
US-20030232985-A1 Succinoylamino heterocycles as inhibitors of a beta protein production APP, BACE1, APH1A POLB 2847/4885LMNA 911/4885ALDH1A1 3091/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.